CASI Projected Dividend Yield

Ord/CASI Pharmaceuticals Inc (New) ( NASDAQ : CASI )

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. Co. is focused on developing and commercializing therapeutics and pharmaceutical products in China, the U.S., and throughout the world. Co. is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the U.S.. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI.

21 YEAR PERFORMANCE RESULTS

CASI Dividend History Detail
CASI Dividend News
CASI Competitors News
# of Shares: 0 Closing Price: 1.94 Current Market Value: 0.00 Cost Basis: 0.00 Date Acquired:
Dividend Cash Flow
Year Annual Dividend Dividend Growth # of Shares Annual Dividend Income Yield On Cost %
2014 0.00 0% 0 $ 0.00 0.00%
2015 0.00 0% 0 $ 0.00 0.00%
2016 0.00 0% 0 $ 0.00 0.00%
2017 0.00 0% 0 $ 0.00 0.00%
2018 0.00 0% 0 $ 0.00 0.00%
2019 0.00 0% 0 $ 0.00 0.00%
2020 0.00 0% 0 $ 0.00 0.00%
2021 0.00 0% 0 $ 0.00 0.00%
2022 0.00 0% 0 $ 0.00 0.00%
2023 0.00 0% 0 $ 0.00 0.00%
2024 0.00 0% 0 $ 0.00 0.00%
2025 0.00 0% 0 $ 0.00 0.00%
2026 0.00 0% 0 $ 0.00 0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection)
0.00
Year
Declaration Date
Ex-Dividend Date
Record Date
Payable Date
Dividend $ Amount
Total:
0.0000
X
Search Dividend Investor